Facility Overview
Located on a 15-acre footprint, the Cambridge site consolidates compounding, aseptic filling, device assembly, packaging, labs, and QA under a single, integrated operation. Multiple cartridge lines support high-volume commercial needs, while flexible aseptic suites accommodate sterile cartridge, PFS, and select vial presentations. Compounding is supported by both mobile tanks and Single Use Systems ranging from small-scale development volumes to commercial scale, enabling efficient process transfer without introducing new facility transitions.
Operations run continuously, reinforced by digitalized GMP systems, seasoned operators, and a long-standing culture of inspection readiness.
Strategic Advantage: A North American Sterile Injectables CDMO
Cambridge offers a unique logistics advantage for pharma and biotech partners seeking reliable, cross-border supply. Situated near the Toronto biotechnology corridor and within efficient reach of major U.S. pharma hubs, the site enables fast distribution, simplified oversight, and resilient supply chain management. Additionally, backed by the mutual recognition agreement between Health Canada and the European Medicines Agency, Novocol Pharma is well positioned to support European and global supply. For companies seeking a sterile injectables CDMO in Canada with deep cartridge expertise and North American proximity, Novocol Pharma provides a strategically positioned alternative to U.S.-based manufacturers.
Reliable cross-border supply
Near the Toronto biotechnology corridor
Within efficient reach of major US and global supply
GMP Performance and Compliance You Can Depend On
Novocol Pharma’s regulatory history demonstrates consistent, repeatable performance. The facility has achieved compliant outcomes across multiple FDA and Health Canada inspections, as well as successive ISO 13485 audits. Media fill programs have successfully completed more than 500,000 units with zero growth-positive results, underscoring the strength of aseptic controls and operator proficiency.
Additional GMP strengths include:
- Integrated QC chemistry and microbiology support
- Established environmental monitoring and sterility assurance systems
- Cold-chain infrastructure spanning +2 to 8°C, −10 to −20°C, and larger −20/−40°C walk-ins for development and commercial programs
- Ability to support BSL-2 products in designated suites, pending final qualification of decontamination systems
Heritage Backed by Septodont’s Global Leadership in Cartridge Manufacturing
Novocol Pharma’s capabilities are strengthened by its place within the Septodont Group, a global leader with more than 95 years of experience in sterile injectable cartridge manufacturing and over 600 million doses produced annually. This legacy provides the technical lineage, operational rigor, and long-term investment that underpin Novocol Pharma’s cartridge and combination-product expertise. Being part of Septodont also ensures financial stability and a culture built around quality, safety, and high-volume sterile performance.
Why Global Pharma and Biotech Partners Choose Novocol Pharma
Development partners consistently reference the accessibility of technical experts, the depth of operational knowledge, and the clarity of cross-functional communication. From the first visit through scale-up, teams have direct access to engineering, MS&T, QC, and operations leads. Many senior personnel have advanced through the facility for over a decade, contributing to a culture of technical ownership and manufacturing pride. This continuity helps reduce onboarding friction, accelerate issue resolution, and build confidence in long-term commercial support.
Novocol Pharma’s manufacturing campus is selected by programs that need:
Integrated sterile operations
Aseptic filling, compounding, assembly, and packaging live under one roof, minimizing transfer points.
Proven regulatory reliability
A long track record of compliant Global Health Authority and ISO inspections reduces regulatory risk.
Scalable infrastructure
Scalable cartridge and RTU capability, flexible aseptic suites, and planned expansion support long-term commercialization.
North American proximity
Canadian manufacturing with ready access to U.S., European and global markets improves distribution timelines and supply chain confidence.